mProX™ Human KIF5B Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Rat hippocampal neurons

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research

Related Diseases

Skeletal Muscle Disease; Kearns-Sayre Syndrome

Gene ID

Human:3799

UniProt ID

Human:P33176

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

KIF5B is a gene that has been implicated in various types of cancer, including combined large cell neuroendocrine carcinoma (C-LCNEC), non-small cell lung cancer (NSCLC), pulmonary sarcomatoid carcinoma (PSC), and colorectal carcinoma (CRC). In C-LCNEC, KIF5B/RET fusion mutation was detected, and adjuvant chemotherapy with a small cell lung cancer (SCLC) regimen was found to improve disease-free survival and overall survival. In NSCLC, KIF5B-RET fusion was identified as a potential therapeutic target, and treatment with the RET inhibitor pralsetinib showed promising results. In PSC, KIF5B-RET fusion was also detected, and treatment with trametinib was effective. In CRC, RET fusions were found to be a unique molecular subset, and RET fusion-positive CRC may have a higher median tumor mutational burden (TMB) and be commonly microsatellite instability-high (MSI-H). These findings suggest that KIF5B and RET fusions may have important implications for the diagnosis, treatment, and management of these types of cancer.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human KIF5B Stable Cell Line (S01YF-1023-PY139). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Taylor Johnson (Verified Customer)

What is the role of KIF5B in pancreatic cancer? Feb 14 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

KIF5B has been identified as a potential biomarker for early pancreatic cancer, particularly in the tumor microenvironment. Feb 14 2021

chat Morgan Brown (Verified Customer)

How does KIF5B mutation affect skeletal development? Sep 19 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Heterozygous KIF5B variants can cause kyphomelic dysplasia, a specific form of skeletal abnormality. Sep 19 2023

Published Data

Fig.1 When hippocampal neurons were subjected to shRNA targeting KIF5B to induce the loss of mushroom spines, the simultaneous expression of a chimeric KIF5A variant incorporating the carboxyl-terminus of KIF5B effectively reversed the spine phenotype.

In experiments involving dissociated rat hippocampal neurons, distinct visual representations were observed in cells co-transfected with GFP and KIF5B-shRNA, either with or without KIF5B, KIF5A, or a chimeric KIF5A/B construct containing the carboxyl-terminus of KIF5B (1-938 KIF5A+941-963 KIF5B). Notably, the reduction in mushroom spines induced by KIF5B-shRNA was effectively reversed by the co-expression of the chimeric KIF5A/B construct. Quantitative analysis was conducted on 32-37 neurons from each group across three independent experiments, revealing significant differences (***p<0.001, ****p<0.0001; Kruskal-Wallis test) in spine density.

Ref: Zhao, Junjun, et al. "Specific depletion of the motor protein KIF5B leads to deficits in dendritic transport, synaptic plasticity and memory." elife 9 (2020): e53456.

Pubmed: 31961321

DOI: 10.7554/eLife.53456

Research Highlights

Zhu, Zirui. et al. "Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature." Journal of cardiothoracic surgery, 2023.
Combined large cell neuroendocrine carcinoma (C-LCNEC) is associated with poor prognosis and the optimal treatment for both LCNEC and C-LCNEC patients remains uncertain. Current research on C-LCNEC treatment options is limited and there is no clear consensus. This abstract explores the challenges and controversies surrounding the management of C-LCNEC, highlighting the need for further investigation into effective treatment strategies for this aggressive form of cancer. It evaluates the available evidence and provides insights into potential future directions for treatment protocols.
Zhu, Zirui. et al. "Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature." Journal of cardiothoracic surgery, 2023.
Pubmed: 37653509 DOI: 10.1186/s13019-023-02349-4

Bi, Yinghui. et al. "Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non,Äësmall cell lung cancer with on,Äëtherapy circulating tumor biomarker monitoring: A case report." Oncology letters, 2023.
Ongoing investigations of targeted therapeutic agents and their increased clinical applications, together with research in genomics and proteomics, have led to the development of innovative treatment approaches for lung cancer. "Molecular subtypes" have also been identified based on specific actionable genetic aberrations. Liquid biopsies, which include circulating tumor DNA testing, have proven to be valuable tools for cancer diagnosis and comprehensive genomic profiling. A case report is presented describing a 66-year-old male patient with advanced non-small cell lung cancer who underwent conventional therapy. Regular monitoring, including continuous ctDNA analysis, was conducted alongside imaging and assessment of tumor markers. The patient initially presented with deep vein thrombosis, with further testing revealing advanced, unresectable disease. Next-generation sequencing confirmed the presence of driver mutation-negative genes.
Bi, Yinghui. et al. "Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non,Äësmall cell lung cancer with on,Äëtherapy circulating tumor biomarker monitoring: A case report." Oncology letters, 2023.
Pubmed: 37600327 DOI: 10.3892/ol.2023.13993